Cargando…

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer

Detalles Bibliográficos
Autor principal:	Ghallab, Ahmed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Leibniz Research Centre for Working Environment and Human Factors 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658461/ https://www.ncbi.nlm.nih.gov/pubmed/33192212 http://dx.doi.org/10.17179/excli2020-2869

Ejemplares similares

Prediction of neoadjuvant chemotherapy response in breast cancer
por: Myllys, Maiju
Publicado: (2021)

Neoadjuvant radiotherapy in triple-negative breast cancer: “the past should not steal the present or hide the future”
por: To, Nhu Hanh, et al.
Publicado: (2022)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Yoon Yang, et al.
Publicado: (2016)

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
por: Zhang, Wei, et al.
Publicado: (2023)

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
por: Zapperi, Stefano, et al.
Publicado: (2023)

Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer
por: Bao, Jean, et al.
Publicado: (2015)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
por: Bertucci, François, et al.
Publicado: (2023)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Comment on “Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer”
por: Altundag, Kadri
Publicado: (2017)

Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
por: Asano, Yuka, et al.
Publicado: (2018)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
por: Talamantes, Sarah, et al.
Publicado: (2020)

Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy
por: Zhao, Yanding, et al.
Publicado: (2020)

A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients
por: Zheng, Tianzhi, et al.
Publicado: (2019)

NMR-Based Metabolomics Analysis Predicts Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: He, Xiangming, et al.
Publicado: (2021)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
por: van den Ende, Nadine S., et al.
Publicado: (2023)

Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Omar, Mohamed, et al.
Publicado: (2023)

Pathological features of triple‐negative breast cancers that showed progressive disease during neoadjuvant chemotherapy
por: Tanabe, Yuko, et al.
Publicado: (2017)

Neoadjuvant Chemotherapy Combined with Breast-Conserving Surgery in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
por: Sarradin, Victor, et al.
Publicado: (2021)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'
por: Kuerer, Henry M, et al.
Publicado: (2016)

Neoadjuvant chemotherapy alters peripheral and tumour‐infiltrating immune cells in breast cancer revealed by single‐cell RNA sequencing
por: Zhou, Hanlin, et al.
Publicado: (2021)

Reply to Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'
por: Heil, Joerg
Publicado: (2016)

Response to: Comment on ‘Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'
por: Shin, Vivian Y, et al.
Publicado: (2016)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response
por: Mohammed, Amrallah A, et al.
Publicado: (2020)

Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer?
por: Atkins, Jordan J., et al.
Publicado: (2013)

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer
por: Chen, Victor E., et al.
Publicado: (2017)

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Meyer, Braydon, et al.
Publicado: (2021)

Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
por: Cavallone, Luca, et al.
Publicado: (2020)

Prediction of Tumor Progression During Neoadjuvant Chemotherapy and Survival Outcome in Patients With Triple-Negative Breast Cancer
por: Yoen, Heera, et al.
Publicado: (2023)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o0k35ns0ad4haj837nn2q20rjq